Clinical Trial Update: CS-121 APOC3 Base Editing in FCS [EARLY_Phase 1]

View source ↗

Summary

Early-phase trial update for CS-121 APOC3 base editing for familial chylomicronemia syndrome, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Chylomicronemia Syndrome

Drugs mentioned

• CS-121 (APOC3 base editing)

Snippet

Sponsor: CorrectSequence Therapeutics Co., Ltd | Conditions: Familial Chylomicronemia Syndrome (FCS) | EARLY_Phase 1 | Status: RECRUITING